Relative Bioavailability Among Different Eutropin Formulations

• Sponsor: LG Chem (Industry)
• Overall Status: Unknown status
• CT.gov ID: NCT03154840
• Collaborator: (none)
• Enrollment: 24
• Location: 1
• Arms: 3
• Anticipated Duration (Months): 6
• Patients Per Site Per Month: 4

Study Details

Study Description

Brief Summary

1. Compares and evaluates the relative bioavailability of single-dose subcutaneous administration of each of the Eutropin formulations to healthy male volunteers.

2. Ensure safety and tolerability of single, subcutaneous administration of Eutropin formulations to healthy male volunteers.

Condition or Disease	Intervention/Treatment	Phase
Relative Bioavailability	Drug: Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU	Phase 1

Study Design

• Study Type: Interventional
• Actual Enrollment: 24 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Intervention Model Description: 6x3 Crossover Study6x3 Crossover Study
• Masking: None (Open Label)
• Primary Purpose: Health Services Research
• Official Title: A Randomized, Open Label, Single Subcutaneous Dose 6x3 Crossover Study to Investigate the Relative Bioavailability Among Different Eutropin Formulations in Healthy Male Volunteers
• Actual Study Start Date: May 31, 2017
• Actual Primary Completion Date: Jul 10, 2017
• Anticipated Study Completion Date: Nov 30, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Eutropin 4IU	Drug: Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU; Investigate the Relative Bioavailability among Different Eutropin Formulations
Experimental: Eutropin AQ 12IU	Drug: Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU; Investigate the Relative Bioavailability among Different Eutropin Formulations
Experimental: Eutropin Pen 36IU	Drug: Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU; Investigate the Relative Bioavailability among Different Eutropin Formulations

Outcome Measures

Primary Outcome Measures

1. AUClast of somatropin [Total three period at weekly intervals (Week 1, Week2, Week3)]

   Pharmacokinetic assessment

Secondary Outcome Measures

1. Peak Plasma Concentration (Cmax) of somatropin [Total three period at weekly intervals (Week 1, Week2, Week3)]

   Pharmacokinetic assessment

2. Area under the plasma concentration versus time curve (AUCinf) of somatropin [Total three period at weekly intervals (Week 1, Week2, Week3)]

   Pharmacokinetic assessment

3. Time at which the Cmax is observed (Tmax) of somatropin [Total three period at weekly intervals (Week 1, Week2, Week3)]

   Pharmacokinetic assessment

4. Elimination half-life time (t1/2β) of somatropin [Total three period at weekly intervals (Week 1, Week2, Week3)]

   Pharmacokinetic assessment

5. IGF-1 [Total three period at weekly intervals (Week 1, Week2, Week3)]

   Pharmacodynamic assessment

6. IGF-BP3 [Total three period at weekly intervals (Week 1, Week2, Week3)]

   Pharmacodynamic assessment

7. Monitoring of adverse reactions [Week -4(Screening), Week 1, Week 2, Week 3, Week 5]

   Clinical significance is assessed by reviewing the general findings of individual subjects individually, and when there is a specific or tendency, analysis is conducted

8. Physical examination [Week -4(Screening), Week 1, Week 2, Week 3, Week 5]

   Weight, Height

9. Vital Signs [Week -4(Screening), Week 1, Week 2, Week 3, Week 5]

   Left-sided blood pressure (systolic / diastolic), pulse rate, tympanic temperature

10. Electrocardiogram [Week -4(Screening), Week 1, Week 2, Week 3, Week 5]

    Ventricular rate, PR interval, QRS, QT/QTc

11. Laboratory test [Week -4(Screening), Week 1, Week 2, Week 3, Week 5]

    General blood test, general chemical test, clinical chemistry urinalysis, pancreas test

12. Injection site reaction and Pain scale evaluation [Week 1, Week 2, Week 3]

    Ask the NRS about the degree of pain and evaluate it as 0-10

Eligibility Criteria

Criteria

• Ages Eligible for Study: 19 Years to 40 Years
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

1. A healthy male who is at least 19 years old but under 40 years of age at screening visit

2. Those who weigh more than 50 kg at screening visit and whose body mass index (BMI) is greater than 19 kg / m2 but less than 28 kg / m2

3. The result of the vital signs in the screening period.

4. A person who is judged to be clinically insignificant in terms of physical or mental condition when the examinee medically judges the screening period physical examination

5. Those who are not clinically significant when the examiner has medically judged the results of examination other than the items described in 17) and 18) of the exclusion criterion in the diagnosis laboratory test results in the screening period

6. A person who consents to use a combination of effective contraceptive methods or medically appropriate contraceptive methods from the first administration of the clinical trial drug to the fourth administration (28 days) after the last administration of the drug for clinical trial and not to provide sperm

7. Those who voluntarily decide to participate in clinical trials and observe the test subjects' precautions and agree in writing

Exclusion Criteria:

1. Those who with a history or history of diabetes

2. Those who with a history or history of malignancy

3. Those who with a history or history of musculoskeletal disorders (including epiphyseal closure, scoliosis, etc.)

4. Those who with history or history of endocrine system (including hypothyroidism, panhypopituitarism, etc.)

5. Those who have a history of skin disease, including psoriasis and contact dermatitis, or who can not exclude the possibility of skin disease under the judgment of the examiner on physical examination conducted at the screening visit.

6. Exclusion Criteria In addition to items 1) to 5), there are other clinically significant history or history of liver, kidney, digestive system, respiratory system, neuropsychiatry, blood /

7. Persons with a history of somatropin and octreotide acetate or hypersensitivity reactions to cresol, glycerol or other drugs (non-steroidal anti-inflammatory drugs, antibiotics, etc.)

8. Those who have participated in other clinical trials or bioequivalence tests within 90 days of the screening visit date

9. Within 60 days before screening visit Those who have received blood (blood, whole blood, etc.) or blood transfusions

10. Those who ingest herbal medicines or health functional foods within 14 days before the screening visit or those who are expected to affect the clinical trial within 7 days

11. Within 14 days prior to screening visit, special medicines that may affect the clinical trial, or those who use general medicines within 7 days

12. Screening Within 30 days prior to the visiting date Alcohol Abuse (alcohol-containing beverage> 21 units / week)

13. Over 30 days before screening visit Overcame smoker (cigarette> 10 cigarettes / day)

14. Within 7 days of screening visit Caffeine-containing foods Excessive intake (caffeinated foods> 3 times / week)

15. Screening Within 7 days prior to the visit Date of intake of food containing xanthine

16. As a result of urine nicotine test or urine drug screening test during the screening period

17. Screening period serum test (hepatitis B test, human immunodeficiency virus (HIV) test, hepatitis C test, syphilis test) Result positive

18. Diagnosis of Screening Period In the case of a laboratory test, one or more of the following findings

• Fasting glucose> 110 mg / dL

• TSH Reference Range Above upper limit or below lower limit

• IGF-1 and IGFBP-3 according to the age of the test subjects. Reference range Above upper limit or below lower limit

• Vitamin B12 Reference range above or below the upper limit

• Insulin reference range above or below the upper limit

• More than twice the AST or ALT or Alkaline Phosphatase (ALP) reference range upper limit

• More than 1.5 times the upper limit of the bilirubin total reference range

1. A 12-electrode electrocardiogram in the screening period revealed a QTc> 450 ms or clinically significant abnormalities

2. Those who are judged to be inadequate to perform the clinical trial when the examiners judge them for other reasons

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Asan Medical Center	Seoul		Korea, Republic of

Sponsors and Collaborators

• LG Chem

Investigators

• Principal Investigator: Kyun-Seop Bae, AIDS Malignancy Consortium

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: LG Chem
• ClinicalTrials.gov Identifier: NCT03154840
• Other Study ID Numbers: LG-HGCL009
• First Posted: May 16, 2017
• Last Update Posted: Jul 21, 2017
• Last Verified: Jul 1, 2017

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Study Results

No Results Posted as of Jul 21, 2017